A multicenter, retrospective chart review study comparing index therapy change rates in open-angle glaucoma or ocular hypertension patients newly treated with latanoprost or travoprost-Z monotherapy

2011

Comparing Therapy Change Rates in Glaucoma Patients Treated with Latanoprost or Travoprost-Z

Sample size: 900 publication Evidence: moderate

Author Information

Author(s): Fain Joel M, Kotak Sameer, Mardekian Jack, Bacharach Jason, Edward Deepak P, Rauchman Steven, Brevetti Teresa, Fox Janet L, Lovelace Cherie

Primary Institution: Pfizer Ophthalmics

Hypothesis

The rate of index therapy change would be lower with travoprost-Z preserved with SofZia than with latanoprost preserved with BAK.

Conclusion

Medication changes were common in both treatment groups but statistically significantly more frequent with travoprost-Z.

Supporting Evidence

Patients treated with travoprost-Z were 52% more likely to change therapy within the first six months.
Insufficient IOP control was the most commonly reported reason for therapy change.
Hyperemia was reported significantly more frequently among those treated with travoprost-Z.

Takeaway

Doctors looked at patient records to see how often people had to change their eye medicine. They found that more people had to switch from travoprost-Z than from latanoprost.

Methodology

A retrospective chart review was conducted at 14 clinical practice sites, analyzing medical records of patients with open-angle glaucoma or ocular hypertension who were treated with latanoprost or travoprost-Z.